Literature DB >> 6588361

Antibody production following immunization with diphtheria and tetanus toxoids in children receiving chemotherapy during remission of malignant disease.

F H Kung, H A Orgel, W W Wallace, R N Hamburger.   

Abstract

Twenty-seven children with various childhood malignancies who were in clinical remission and receiving maintenance chemotherapy were given diphtheria-pertussis-tetanus (DPT) immunizations. Antidiphtheria and antitetanus titers were drawn before and 1 month after immunization. Only one child had no antibody response to either antigen. Two other children failed to develop any detectable antitetanus antibody titer but did mount a normal antibody response to inactivated diphtheria antigen. In fact, most children made good antibody responses to both immunizing antigens, irrespective of the nature of their disease or of the treatment given. These results show that children receiving long-term chemotherapy should not be denied the protection afforded by immunization with nonliving vaccines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6588361

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

Review 1.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

2.  Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation.

Authors:  Avinash K Shetty; Mary A Winter
Journal:  Ochsner J       Date:  2012

3.  Vaccination Against Diphtheria and Tetanus as a Way to Activate Adaptive Immunity in Children with Solid Tumors.

Authors:  Mikhail Petrovich Kostinov; Nelli Kimovna Akhmatova; Svetlana Victorovna Karpocheva; Anna Egorovna Vlasenko; Valentina Borisovna Polishchuk; Anton Mikhailovich Kostinov
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.